The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a Joint Declaration on Cooperation in the Fight against Doping in Sport today in Lausanne, Switzerland.
The Declaration was signed by Mr. David Howman, Director General of WADA, and Mr. Haruo Naito, President of the IFPMA and President and CEO of Eisai.
From left to right: Dr. Yves Juillet, Chair of the Regulatory Policy and Technical Standards Committee of IFPMA; Mr. Haruo Naito, President of IFPMA; Mr. David Howman, Director General of WADA; and Dr. Olivier Rabin, Science Director of WADA.
The Declaration aims to facilitate voluntary cooperation between WADA and IFPMA member companies, to identify medicinal compounds with doping potential, minimize misuse of medicines still in development, improve the flow of relevant information and facilitate development of detection methods in the context of the fight against doping in sport.
In a written statement, the Hon. John Fahey said: “We are very pleased that the IFPMA will be cooperating actively with WADA in the fight against doping in sport. As soon as a reliable method to detect a particular doping compound in athletes is developed, dopers start looking for a new compound which might enhance performance. Working closely with pharmaceutical companies to identify new potential doping compounds before they enter clinical trials should facilitate much faster development of detection methods, which will benefit clean athletes worldwide.”
Mr. Haruo Naito commented: “IFPMA members recognize that medicines may be misused to enhance sporting performance, thereby creating unfair competition and putting athletes’ health and even lives at risk. With pharmaceutical companies working hand-in-hand with WADA, more resources will be brought to bear on the scourge of doping, leading to cleaner sports and healthier athletes.”
On the pharmaceutical industry side, the Declaration was championed by the IFPMA’s Regulatory Policy and Technical Standards (RPTS) Committee. As with pharmaceutical industry positions on other important issues, the Declaration was specifically reviewed and approved by the regional or national pharmaceutical industry associations covering the European Union (EFPIA), Japan (JPMA) and the USA (PhRMA).
The Declaration has been inspired by a number of successful bilateral collaborative exercises between WADA and individual pharmaceutical companies, including Merck & Co., Inc. and Roche.
Click here for Mr. Howman’s opening remarks.
Click here for Mr. Naito’s opening remarks.
About the IFPMA
The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical industry, including the biotech and vaccine sectors. Its members comprise 25 leading international companies and 46 national and regional industry associations covering developed and developing countries. The industry’s R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA’s Ethical Promotion online resource (www.ifpma.org/EthicalPromotion/) and its Developing World Health Partnerships Directory (www.ifpma.org/HealthPartnerships) help make the industry’s activities more transparent. The IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety, and coordinates industry participation in the WHO IMPACT initiative to combat counterfeit medicines. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).